Acceleron Pharma reported $448M in Current Assets for its second fiscal quarter of 2020.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Assets Change
Acceleron Pharma XLRN:US $ 448M 16M
Akebia Therapeutics AKBA:US $ 391M 58.1M
Alexion Pharmaceuticals ALXN:US $ 5367.9M 497.7M
Amgen AMGN:US $ 22895M 4082M
Bayer BAYN:GR 3.28B 24.6M
Biomarin Pharmaceutical BMRN:US $ 2647.57M 531.32M
Bluebird Bio BLUE:US $ 1613.44M 645.98M
Clovis Oncology CLVS:US $ 322M 21M
Dicerna Pharmaceuticals DRNA:US $ 627.65M 54.11M
Eli Lilly And LLY:US $ 14581.9M 587.7M
Exelixis EXEL:US $ 1394M 258M
Gilead Sciences GILD:US $ 24643M 2307M
GlaxoSmithKline GSK:LN 2.3B 95.5M
Johnson & Johnson JNJ:US $ 57578M 11686M
Neurocrine Biosciences NBIX:US $ 1146M 178M
Novartis NOVN:VX 23.88B 784M
Pfizer PFE:US $ 46424M 11686M
Ptc Therapeutics PTCT:US $ 605.02M 86.9M
Puma Biotechnology PBYI:US $ 159M 1M
Regeneron Pharmaceuticals REGN:US $ 7860.2M 783.9M
Ultragenyx Pharmaceutical RARE:US $ 906.04M 11.72M
United Therapeutics UTHR:US $ 1894.4M 48.1M
Vertex Pharmaceuticals VRTX:US $ 6694.32M 1247.92M